Company Performance Metrics
- Sylvain Lengacher: Co-CEO, OPERATING & TECHNOLOGY & Co-Founder
- Charles Finsterwald: Chief Scientific Officer, Co-founder
GliaPharm is a Swiss-based biotechnology company that offers treatments for neurological and psychiatric disorders.
GliaPharm's innovative therapeutic approach is to target glial cells , the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Their vision is to become a leading
biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.
GliaPharm is a Swiss biotechnology company active in the development of treatments for neurological and psychiatric diseases.
The innovative therapeutic approach of GliaPharm is to target glial cells , or 'support cells' of neurons, to support and improve brain metabolism under certain pathological conditions. Their vision is to become a leader in the development of glial cell targeting agents that act as neuroprotective agents and maintain cognitive functions.
